Physician profile
Dean P Sutherland
NPI 1346251089
$39,740.31
in general payments reported to CMS, 2019-2025
51 companies · $1,358 in 2025
The $1,358 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $17K · 2021: $11K · 2022: $5,257 · 2023: $1,522 · 2024: $1,588 · 2025: $1,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $12,874.87 | 2019-2024 | Rytary, Ongentys |
| Acorda Therapeutics, INC | $11,667.53 | 2019-2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $7,055.00 | 2020-2021 | |
| Abbvie INC. | $1,578.32 | 2019-2025 | Botox, Duopa, Ubrelvy |
| Abbott Laboratories | $614.97 | 2023-2025 | Infinity |
| Ge Healthcare | $540.95 | 2019-2025 | |
| Ucb, INC. | $524.66 | 2019-2024 | Zilbrysq |
| Neurocrine Biosciences, INC. | $460.01 | 2019-2024 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $333.97 | 2019-2025 | Qelbree, Gocovri, Gocovri |
| Allergan, INC. | $297.44 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $286.84 | 2019-2024 | Ultomiris |
| Acadia Pharmaceuticals INC | $264.70 | 2019-2025 | Nuplazid, Daybue |
| Teva Pharmaceuticals USA, INC. | $204.10 | 2019-2024 | Austedo Xr |
| Kyowa Kirin, INC. | $198.28 | 2019-2024 | Nourianz |
| Amgen INC. | $193.57 | 2019-2025 | Uplizna |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $176.55 | 2019-2020 | |
| Insightec,INC | $171.11 | 2023-2024 | Exablate |
| Adamas Pharmaceuticals, INC. | $161.72 | 2019-2020 | |
| Revance Therapeutics, INC. | $157.77 | 2024-2025 | Daxxify |
| Takeda Pharmaceuticals U.S.A., INC. | $139.91 | 2022-2024 | Hyqvia, Gammagard |
| Astrazeneca Pharmaceuticals LP | $134.98 | 2023-2025 | Andexxa, Wainua |
| Pfizer INC. | $134.15 | 2023-2025 | |
| Medtronic, INC. | $120.70 | 2025 | Sensight, Percept PC Brainsense |
| Catalyst Pharmaceuticals, INC. | $118.49 | 2021-2025 | |
| Argenx US, INC. | $112.14 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $107.01 | 2021-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $102.72 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $96.02 | 2022-2025 | Onpattro |
| Biohaven Pharmaceutical Holding Company LTD. | $75.63 | 2022 | |
| Neurelis, INC. | $71.98 | 2021-2025 | Valtoco |
| Greenwich Biosciences, INC. | $71.93 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $69.79 | 2024-2025 | Xeomin, Inbrija |
| Medtronic USA, INC. | $63.44 | 2019 | |
| Eisai INC. | $56.62 | 2022-2025 | |
| Horizon Therapeutics Plc | $46.22 | 2022-2023 | Uplizna |
| Tanabe Pharma America, INC. | $46.16 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $45.13 | 2019 | |
| Grifols USA, LLC | $42.85 | 2019-2025 | Gamunex-C |
| Avion Pharmaceuticals | $41.69 | 2021-2022 | |
| Boston Scientific Corporation | $35.52 | 2019-2025 | Vercise |
| Amylyx Pharmaceuticals, INC. | $33.53 | 2023 | Relyvrio |
| Lilly USA, LLC | $33.30 | 2022-2023 | Amyvid |
| Corium, LLC | $29.69 | 2022 | |
| Akcea Therapeutics, INC. | $29.39 | 2020 | |
| Janssen Biotech, INC. | $22.91 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $19.07 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $18.48 | 2021 | |
| Biogen, INC. | $18.07 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.86 | 2022 | |
| Grt US Holding, INC. | $12.82 | 2020 | |
| Zyla Life Sciences, INC. | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.